Cargando…
ELF5 isoform expression is tissue-specific and significantly altered in cancer
BACKGROUND: E74-like factor 5 (ELF5) is an epithelial-specific member of the E26 transforming sequence (ETS) transcription factor family and a critical regulator of cell fate in the placenta, pulmonary bronchi, and milk-producing alveoli of the mammary gland. ELF5 also plays key roles in malignancy,...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4704400/ https://www.ncbi.nlm.nih.gov/pubmed/26738740 http://dx.doi.org/10.1186/s13058-015-0666-0 |
_version_ | 1782408858196508672 |
---|---|
author | Piggin, Catherine L. Roden, Daniel L. Gallego-Ortega, David Lee, Heather J. Oakes, Samantha R. Ormandy, Christopher J. |
author_facet | Piggin, Catherine L. Roden, Daniel L. Gallego-Ortega, David Lee, Heather J. Oakes, Samantha R. Ormandy, Christopher J. |
author_sort | Piggin, Catherine L. |
collection | PubMed |
description | BACKGROUND: E74-like factor 5 (ELF5) is an epithelial-specific member of the E26 transforming sequence (ETS) transcription factor family and a critical regulator of cell fate in the placenta, pulmonary bronchi, and milk-producing alveoli of the mammary gland. ELF5 also plays key roles in malignancy, particularly in basal-like and endocrine-resistant forms of breast cancer. Almost all genes undergo alternative transcription or splicing, which increases the diversity of protein structure and function. Although ELF5 has multiple isoforms, this has not been considered in previous studies of ELF5 function. METHODS: RNA-sequencing data for 6757 samples from The Cancer Genome Atlas were analyzed to characterize ELF5 isoform expression in multiple normal tissues and cancers. Extensive in vitro analysis of ELF5 isoforms, including a 116-gene quantitative polymerase chain reaction panel, was performed in breast cancer cell lines. RESULTS: ELF5 isoform expression was found to be tissue-specific due to alternative promoter use but altered in multiple cancer types. The normal breast expressed one main isoform, while in breast cancer there were subtype-specific alterations in expression. Expression of other ETS factors was also significantly altered in breast cancer, with the basal-like subtype demonstrating a distinct ETS expression profile. In vitro inducible expression of the full-length isoforms 1 and 2, as well as isoform 3 (lacking the Pointed domain) had similar phenotypic and transcriptional effects. CONCLUSIONS: Alternative promoter use, conferring differential regulatory responses, is the main mechanism governing ELF5 action rather than differential transcriptional activity of the isoforms. This understanding of expression and function at the isoform level is a vital first step in realizing the potential of transcription factors such as ELF5 as prognostic markers or therapeutic targets in cancer. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13058-015-0666-0) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4704400 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-47044002016-01-08 ELF5 isoform expression is tissue-specific and significantly altered in cancer Piggin, Catherine L. Roden, Daniel L. Gallego-Ortega, David Lee, Heather J. Oakes, Samantha R. Ormandy, Christopher J. Breast Cancer Res Research Article BACKGROUND: E74-like factor 5 (ELF5) is an epithelial-specific member of the E26 transforming sequence (ETS) transcription factor family and a critical regulator of cell fate in the placenta, pulmonary bronchi, and milk-producing alveoli of the mammary gland. ELF5 also plays key roles in malignancy, particularly in basal-like and endocrine-resistant forms of breast cancer. Almost all genes undergo alternative transcription or splicing, which increases the diversity of protein structure and function. Although ELF5 has multiple isoforms, this has not been considered in previous studies of ELF5 function. METHODS: RNA-sequencing data for 6757 samples from The Cancer Genome Atlas were analyzed to characterize ELF5 isoform expression in multiple normal tissues and cancers. Extensive in vitro analysis of ELF5 isoforms, including a 116-gene quantitative polymerase chain reaction panel, was performed in breast cancer cell lines. RESULTS: ELF5 isoform expression was found to be tissue-specific due to alternative promoter use but altered in multiple cancer types. The normal breast expressed one main isoform, while in breast cancer there were subtype-specific alterations in expression. Expression of other ETS factors was also significantly altered in breast cancer, with the basal-like subtype demonstrating a distinct ETS expression profile. In vitro inducible expression of the full-length isoforms 1 and 2, as well as isoform 3 (lacking the Pointed domain) had similar phenotypic and transcriptional effects. CONCLUSIONS: Alternative promoter use, conferring differential regulatory responses, is the main mechanism governing ELF5 action rather than differential transcriptional activity of the isoforms. This understanding of expression and function at the isoform level is a vital first step in realizing the potential of transcription factors such as ELF5 as prognostic markers or therapeutic targets in cancer. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13058-015-0666-0) contains supplementary material, which is available to authorized users. BioMed Central 2016-01-07 2016 /pmc/articles/PMC4704400/ /pubmed/26738740 http://dx.doi.org/10.1186/s13058-015-0666-0 Text en © Piggin et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Piggin, Catherine L. Roden, Daniel L. Gallego-Ortega, David Lee, Heather J. Oakes, Samantha R. Ormandy, Christopher J. ELF5 isoform expression is tissue-specific and significantly altered in cancer |
title | ELF5 isoform expression is tissue-specific and significantly altered in cancer |
title_full | ELF5 isoform expression is tissue-specific and significantly altered in cancer |
title_fullStr | ELF5 isoform expression is tissue-specific and significantly altered in cancer |
title_full_unstemmed | ELF5 isoform expression is tissue-specific and significantly altered in cancer |
title_short | ELF5 isoform expression is tissue-specific and significantly altered in cancer |
title_sort | elf5 isoform expression is tissue-specific and significantly altered in cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4704400/ https://www.ncbi.nlm.nih.gov/pubmed/26738740 http://dx.doi.org/10.1186/s13058-015-0666-0 |
work_keys_str_mv | AT piggincatherinel elf5isoformexpressionistissuespecificandsignificantlyalteredincancer AT rodendaniell elf5isoformexpressionistissuespecificandsignificantlyalteredincancer AT gallegoortegadavid elf5isoformexpressionistissuespecificandsignificantlyalteredincancer AT leeheatherj elf5isoformexpressionistissuespecificandsignificantlyalteredincancer AT oakessamanthar elf5isoformexpressionistissuespecificandsignificantlyalteredincancer AT ormandychristopherj elf5isoformexpressionistissuespecificandsignificantlyalteredincancer |